相关实验视频

Updated: May 22, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

探索从素水解酸中提取的,抑制BACE1活性并抑制Aβ蛋白沉积

Kuo-Chiang Hsu¹, Shang-Ming Huang², Jhih-Yi Shen²

¹Department of Nutrition, China Medical University, No.100, Sec.1, Jingmao Rd., Beitun Dist., Taichung City 406040, Taiwan; Department of Food Nutrition and Health Biotechnology, Asia University, 500 Lioufeng Rd., Wufen Dist., Taichung City 41354, Taiwan.

International journal of biological macromolecules

|March 12, 2025

概括

一种新型的,VR-,有效地抑制BACE1,这是阿尔茨海默氏症病原发生的关键酶. 这种阿尔茨海默氏症预防策略降低了粉样β水平,并显示出神经保护的潜力.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
药理学药理学是指药理学的学科.

背景情况:

阿尔茨海默氏症 (AD) 是最常见的痴呆症,其特征是粉样质斑块和神经纤维状结.
目前的AD治疗提供症状缓解,但缺乏治愈潜力和副作用.
由BACE1 (β位APP分裂酶1) 启动的粉样蛋白-β (Aβ) 积累驱动AD病理.

研究的目的:

从G-Bro水解剂中识别和描述一种强大的BACE1抑制剂.
在阿尔茨海默氏症细胞模型中评估孤立的,VR-的神经保护作用.

主要方法:

用纳米UHPLC-ESI Q-TOF质谱分析G-Bro水解剂以确定序列.
进行BACE1抑制试验以分离最有效的,VR-.
使用N2a/PS/APP细胞模型评估VR-对BACE1表达,sAPP分泌和Aβ水平的影响.

主要成果:

VR-显示了63.8%的BACE1抑制率,并将BACE1表达率降低了90%以上.
VR-降低了细胞内Aβ1-42水平超过56%,并将细胞外Aβ平衡转向单体.
该在细胞模型中表现出显著的神经保护潜力.

结论:

作为BACE1抑制剂,VR-对阿尔茨海默病的预防有前途.
它来自水解谷物食品的起源表明它是一个潜在的安全和可访问的治疗来源.
药物输送系统的进一步开发可以提高神经元透率,以有效治疗阿尔茨海默氏症.

关键词:

阿尔茨海默病 (AD) 是一种疾病.粉样蛋白-β (Aβ) 是一种生物活性的生物活性.格里亚丁蛋白质的水解酸.乙-分泌酶 (BACE1) 是一种

更多相关视频

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...